Target Gene Table ▼
VIS IDVirusEnsembl IDGene TypeTarget GeneOncogeneTumor Suppressor GeneNCBI IDUniprot ID
TVIS10037679HBVENSG00000106804.10protein_codingC5NoNo727P01031
TVIS10031602HBVENSG00000106804.10protein_codingC5NoNo727P01031
TVIS10025527HBVENSG00000106804.10protein_codingC5NoNo727P01031
TVIS10024806HBVENSG00000106804.10protein_codingC5NoNo727P01031
TVIS10049406HBVENSG00000106804.10protein_codingC5NoNo727P01031
TVIS10049407HBVENSG00000106804.10protein_codingC5NoNo727P01031
TVIS30000179HIVENSG00000106804.10protein_codingC5NoNo727P01031
TVIS30077807HIVENSG00000106804.10protein_codingC5NoNo727P01031
TVIS30020975HIVENSG00000106804.10protein_codingC5NoNo727P01031
TVIS20031120HPVENSG00000106804.10protein_codingC5NoNo727P01031
TCGA Plot Options ▼
Drug Information ▼
GeneC5
DrugBank IDDB15636
Drug NameZilucoplan
Target IDBE0000855
UniProt IDP01031
Regulation Typeinhibitor
PubMed IDs32736596
CitationsWilkinson T, Dixon R, Page C, Carroll M, Griffiths G, Ho LP, De Soyza A, Felton T, Lewis KE, Phekoo K, Chalmers JD, Gordon A, McGarvey L, Doherty J, Read RC, Shankar-Hari M, Martinez-Alier N, O'Kelly M, Duncan G, Walles R, Sykes J, Summers C, Singh D: ACCORD: A Multicentre, Seamless, Phase 2 Adaptive Randomisation Platform Study to Assess the Efficacy and Safety of Multiple Candidate Agents for the Treatment of COVID-19 in Hospitalised Patients: A structured summary of a study protocol for a randomised controlled trial. Trials. 2020 Jul 31;21(1):691. doi: 10.1186/s13063-020-04584-9.
GroupsApproved
Direct Classification
SMILESCCCCCCCCCCCCCCCC(=O)N[C@@H](CCC(=O)NCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCC(=O)NCCCC[C@H](NC(=O)[C@@H](NC(=O)[C@@H]1CCCN1C(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC1=CNC2=NC=CC=C12)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)N(C)C(=O)[C@@H]1CC(=O)NCCCC[C@H](NC(C)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N1)C(C)(C)C)C1CCCCC1)C(O)=O)C(O)=O
Pathways
PharmGKB
ChEMBL